Impact of COVID-19 Vaccine Type on the Efficacy and Safety of Nivolumab in Patients With Metastatic Non-small-cell Lung Cancer: A Multicenter Study
In Vivo, cilt.40, sa.4, ss.2476-2488, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 40 Sayı: 4
- Basım Tarihi: 2026
- Doi Numarası: 10.21873/invivo.14401
- Dergi Adı: In Vivo
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE, Health Research Premium Collection (ProQuest)
- Sayfa Sayıları: ss.2476-2488
- Anahtar Kelimeler: Covid-19, lung cancer, mRNA-based, nivolumab, virion-based
- İstanbul Kent Üniversitesi Adresli: Hayır
Özet
Background/Aim: The effect of COVID-19 vaccine type on the outcomes of therapy immune checkpoint inhibitors remains unclear, and concerns persist regarding whether mRNA-based vaccines may negatively impact treatment efficacy or increase immune-related toxicity. This study aimed to evaluate the association between COVID-19 vaccination type and the efficacy and safety of nivolumab in patients with metastatic non-small-cell lung cancer (NSCLC). Patients and Methods: We retrospectively analyzed 138 patients with driver-negative metastatic NSCLC treated with second-line nivolumab. Patients were classified as receiving virion-based (Sinovac) only, mRNA-based only, or both types of vaccines. Treatment response, progression-free survival, objective response rate, clinical benefit rate clinical benefit rate and immune-related adverse events were compared. Results: The overall response and clinical benefit rates were similar across vaccination groups, with no significant differences observed (p=0.38 and p=0.16, respectively). Median progression-free survival did not differ significantly among the different groups (p=0.39). The incidence of any-grade and grade 3-4 immune-related adverse events was comparable across groups, although grade 1-2 immune-related adverse events were more frequent among patients who had received at least one dose of Sinovac. Conclusion: In patients with metastatic NSCLC receiving second-line nivolumab, the efficacy and safety profile of nivolumab did not differ according to the type of COVID-19 vaccine patients had received prior to therapy.